David H Abramson, Armida W M Fabius, Jasmine H Francis, Brian P Marr, Ira J Dunkel, Scott E Brodie, Anna Escuder, Y Pierre Gobin
BACKGROUND: Surgical removal of one or both eyes has been the most common way to treat children with retinoblastoma worldwide for more than 100 years. Ophthalmic artery chemosurgery (OAC) was introduced 10 years ago and it has been used as an alternative to enucleation for eyes with advanced retinoblastoma. The purpose of this report is to analyze our 9-year experience treating advanced retinoblastoma eyes with OAC.
MATERIALS AND METHODS: Single-arm retrospective study from a single center of 226 eyes with eyes of retinoblastoma patients with advanced intraocular disease defined as both Reese-Ellsworth (RE) "Va" or "Vb" and International Classification Retinoblastoma (ICRb) group "D" or "E" (COG Classification). Ocular survival, patient survival, second cancers, and electroretinography (ERG) were assessed.
RESULTS: Ocular survival at five years for these advanced eyes was 70.2% (95% confidence interval, 57.3%-79.8%). When eyes were divided into groups either by RE classification or ICRb, no significant differences in ocular survival were seen. Ocular survival was significantly better in naïve compared to non-naïve eyes (80.2% vs 58.4%, p = 0.041). The ERG distribution was very similar before and after OAC treatment for the patient population that did not receive intravitreal chemotherapy. Three patients (1.5%) have developed metastatic retinoblastoma (previously reported) and were successfully treated (no deaths).
CONCLUSION: Using OAC for advanced eyes (the majority of such eyes have been enucleated in the past) enables 70% 5-year ocular survival. Treated eyes have a similar ERG distribution before and after treatment. No patient has died of metastatic retinoblastoma.
Ophthalmology. 2015 May;122(5):1016-22
[PMID:
25616769]
Am J Ophthalmol. 2009 Aug;148(2):192-8
[PMID:
19477707]
PLoS One. 2012;7(4):e34120
[PMID:
22545080]
PLoS One. 2016 Jun 03;11(6):e0156806
[PMID:
27258771]
Arch Ophthalmol. 2011 Nov;129(11):1492-4
[PMID:
22084221]
Annu Rev Med. 2014;65:171-84
[PMID:
24422571]
Ophthalmology. 2008 Aug;115(8):1398-404, 1404.e1
[PMID:
18342944]
Paediatr Drugs. 2015 Jun;17(3):185-98
[PMID:
25742925]
Ophthalmology. 2014 Sep;121(9):1810-7
[PMID:
24819859]
J Pediatr Ophthalmol Strabismus. 2013 Mar-Apr;50(2):106-12
[PMID:
23244241]
Lancet Oncol. 2014 Sep;15(10):1157-67
[PMID:
25126964]
PLoS One. 2012;7(9):e44322
[PMID:
23028521]
Ophthalmology. 2014 Jul;121(7):1453-60
[PMID:
24656794]
Acta Ophthalmol. 2016 Nov;94(7):e644-e651
[PMID:
27214798]
Am J Ophthalmol. 2015 Dec;160(6):1116-1126.e5
[PMID:
26374932]
Retina. 2004 Dec;24(6):828-48
[PMID:
15579980]
Ophthalmology. 2012 Mar;119(3):611-6
[PMID:
22197434]
PLoS One. 2014 Jan 20;9(1):e84247
[PMID:
24465398]
J Clin Oncol. 2014 Oct 10;32(29):3284-90
[PMID:
25185089]
JAMA Ophthalmol. 2015 Nov;133(11):1341-7
[PMID:
26378747]
J Neurosurg Pediatr. 2012 Sep;10(3):175-81
[PMID:
22793160]
PLoS One. 2015 Dec 28;10(12):e0145436
[PMID:
26709699]
JAMA Ophthalmol. 2016 Mar 17;:null
[PMID:
26986443]
Retina. 2012 Apr;32(4):799-804
[PMID:
22105496]
Int J Clin Oncol. 2004 Apr;9(2):69-73
[PMID:
15108036]
Ophthalmol Clin North Am. 2005 Mar;18(1):55-63, viii
[PMID:
15763191]
Ophthalmology. 2015 Jun;122(6):1173-9
[PMID:
25795478]
Br J Ophthalmol. 2008 Sep;92(9):1180-4
[PMID:
18650212]
J AAPOS. 2009 Dec;13(6):546-50
[PMID:
20006813]
Arch Ophthalmol. 2004 Sep;122(9):1316-23
[PMID:
15364710]
J Pediatr Ophthalmol Strabismus. 2013 Sep-Oct;50(5):296-303
[PMID:
23937863]
AMA Arch Ophthalmol. 1954 Apr;53(4):505-13
[PMID:
14360881]
Adolescent
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Child
Child, Preschool
Electroretinography
Eye Enucleation
Female
Humans
Infant
Infusions, Intra-Arterial
Male
Melphalan
Methotrexate
Ophthalmic Artery
Retina
Retinal Neoplasms
Retinoblastoma
Retrospective Studies
Survival Rate
Topotecan
